Mayo Clinic researchers find oncogene is important in pancreatic cancer growth and spread
February 22, 2010 by admin · Leave a Comment
Contact: Paul Scotti
scotti.paul@mayo.edu
904-953-2299
Mayo Clinic Read more
Researchers find biomarkers in saliva for detection of early-stage pancreatic cancer
February 15, 2010 by admin · Leave a Comment
Contact: Sandra Shagat
sshagat@dentistry.ucla.edu
310-206-0835
University of California - Los Angeles Read more
Researchers find drug that reverses resistance to chemotherapy for Pancreatic cancer
For the first time researchers have shown that by inhibiting the action of an enzyme called TAK-1, it is possible to make pancreatic cancer cells sensitive to chemotherapy, opening the way for the development of a new drug to treat the disease.
MicroRNAs circulating in blood show promise as biomarkers to detect pancreatic cancer
September 7, 2009 by admin · Leave a Comment
A blood test for small molecules abnormally expressed in pancreatic cancer may be a promising route to early detection of the disease, researchers at The University of Texas M. D. Anderson Cancer Center report in the September edition of the journal Cancer Prevention Research.
Prion protein identified as a novel early pancreatic cancer biomarker
August 18, 2009 by admin · Leave a Comment
Case Western Reserve researchers follow the prion’s path from mad cow disease to deadly cancer
Mad cow disease is caused by the accumulation of an abnormal protein, the prion, in the brain of an affected patient. Outside of the brain, very little is known about prions. Case Western Reserve University School of Medicine, researchers have, for the first time, identified the prion as a biomarker for pancreatic cancer. Pancreatic cancer is one of the most deadly cancers in humans; the five year survival rate is less than 10 percent.
Herbal extract proven to inhibit the development of pancreatic cancer
April 19, 2009 by admin · Leave a Comment
An herb recently found to kill pancreatic cancer cells also appears to inhibit development of pancreatic cancer as a result of its anti-inflammatory properties, according to researchers from the Kimmel Cancer Center at Jefferson. The data were presented at the AACR 100th Annual Meeting 2009 in Denver. (Abstract #494)
Pfizer Stops Sutent Trial Early, Citing Benefit For Rare Form of Pancreatic Cancer
March 12, 2009 by admin · Leave a Comment
Pfizer Inc. (PFE) said Thursday it stopped a late-stage trial of its drug Sutent early because the drug showed “significant benefit” in patients with a rare form of pancreatic cancer.
The finding is another positive for Sutent, which last month was backed for use in kidney cancer by the U.K. agency that decides which treatments are made available in the publicly funded health-care system in England and Wales, reversing an earlier recommendation. The agency still rejected several other companies’ drugs for kidney cancer. Sutent is approved in the U.S. to treat kidney cancer and a digestive-tract cancer.
Pancreatic tumor growth in mice by inhibiting key protein
February 1, 2009 by admin · Leave a Comment
Researchers at Stanford University School of Medicine have identified a protein critical for the growth of pancreatic cancer. Blocking the expression of the protein slowed or prevented tumor growth in mice and made cultured cancer cells vulnerable to the conditions of low oxygen that occur in solid tumors.
New Cancer Treatment Shrinks Pancreatic Tumor
November 24, 2008 by admin · Leave a Comment
NASHVILLE, Tenn., Nov. 24 — A new cancer treatment is realizing outstanding results against pancreatic cancer. Following five weeks of treatment, a patient’s large, stage 4 tumor was reduced in size by 70%. After seven more weeks of treatment, it no longer could be definitely identified on scans. Pancreatic cancer usually is fatal six to nine months after diagnosis. NeoPlas Innovation’s combination of FDA-approved drugs appears to improve those odds for some patients, based on this result and similar ones seen before the protocol’s public availability.
New treatment combination safe for pancreatic cancer patients
June 2, 2008 by admin · Leave a Comment
Treating pancreatic cancer with a combination of chemotherapy, biotherapy and radiotherapy prior to surgery is safe and may be beneficial for patients, according to a University of Pittsburgh Cancer Institute (UPCI) study presented at the 44th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
